Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland

Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland

Introduction: In Poland, active HCV infection affects between 0.4 and 0.5% of the population, i.e., about 150,000 people, while the number of patients with epilepsy is estimated to be 350,000–400,000. Currently available antiviral therapies show little interaction with neurological drugs. The aim of...

Full description

Bibliographic Details
Main Authors: Monika Pazgan-Simon, Jerzy Jaroszewicz, Krzysztof Simon, Beata Lorenc, Marek Sitko, Dorota Zarębska-Michaluk, Dorota Dybowska, Magdalena Tudrujek-Zdunek, Hanna Berak, Włodzimierz Mazur, Jakub Klapaczyński, Ewa Janczewska, Anna Parfieniuk-Kowerda, Robert Flisiak
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Journal of Personalized Medicine
Subjects:
HCV infection
epilepsy
DAA treatment
Online Access:https://www.mdpi.com/2075-4426/13/7/1111

Internet

https://www.mdpi.com/2075-4426/13/7/1111

Similar Items